FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a cytotoxic cell, which is macrophage, that contains CAR and adenoviral component Ad5f35, as well as to a composition containing it. A method for preparing the specified cytotoxic cell is also disclosed, providing introduction of CAR to macrophage using an adenoviral vector Ad5f35.
EFFECT: invention is effective for the treatment of tumor or cancer, as well as for the stimulation of an immune response to the target tumor cell or tumor tissue in a subject.
22 cl, 28 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2018 |
|
RU2819805C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
